Laura M. Bartle

2.7k total citations
27 papers, 2.2k citations indexed

About

Laura M. Bartle is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Laura M. Bartle has authored 27 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Molecular Biology and 5 papers in Epidemiology. Recurrent topics in Laura M. Bartle's work include HER2/EGFR in Cancer Research (7 papers), Cytomegalovirus and herpesvirus research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Laura M. Bartle is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Cytomegalovirus and herpesvirus research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Laura M. Bartle collaborates with scholars based in United States, France and Italy. Laura M. Bartle's co-authors include Victor S. Goldmacher, Anna Skaletskaya, Thomas Chittenden, Edward S. Mocarski, A. Louise McCormick, Carol A. Vater, Jean D. Sipe, Robert J. Lutz, Nancy Kedersha and Peter U. Park and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Laura M. Bartle

27 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura M. Bartle United States 17 892 845 544 530 276 27 2.2k
Thomas Chittenden United States 11 1.8k 2.1× 712 0.8× 525 1.0× 1.5k 2.9× 179 0.6× 25 3.4k
William McCulloch United States 21 1.4k 1.5× 419 0.5× 277 0.5× 484 0.9× 164 0.6× 87 2.5k
Jean-Philippe Stéphan France 25 1.3k 1.4× 299 0.4× 343 0.6× 405 0.8× 50 0.2× 36 2.2k
David Maussang Netherlands 20 794 0.9× 553 0.7× 670 1.2× 691 1.3× 64 0.2× 23 2.0k
Marianne Kraus Switzerland 21 1.4k 1.6× 471 0.6× 441 0.8× 537 1.0× 88 0.3× 48 2.2k
Rémi Fagard France 30 1.0k 1.2× 247 0.3× 819 1.5× 922 1.7× 52 0.2× 72 2.6k
Christopher J. Farady Switzerland 16 1.6k 1.8× 219 0.3× 692 1.3× 136 0.3× 79 0.3× 22 2.3k
Dorothy Hudig United States 28 1.1k 1.2× 213 0.3× 1.1k 2.0× 518 1.0× 34 0.1× 79 2.4k
Denis Martinvalet United States 25 1.2k 1.3× 359 0.4× 886 1.6× 389 0.7× 44 0.2× 43 2.3k
Jens Dhein Germany 13 2.6k 3.0× 590 0.7× 2.5k 4.6× 867 1.6× 74 0.3× 24 4.8k

Countries citing papers authored by Laura M. Bartle

Since Specialization
Citations

This map shows the geographic impact of Laura M. Bartle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura M. Bartle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura M. Bartle more than expected).

Fields of papers citing papers by Laura M. Bartle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura M. Bartle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura M. Bartle. The network helps show where Laura M. Bartle may publish in the future.

Co-authorship network of co-authors of Laura M. Bartle

This figure shows the co-authorship network connecting the top 25 collaborators of Laura M. Bartle. A scholar is included among the top collaborators of Laura M. Bartle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura M. Bartle. Laura M. Bartle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patel, Chirag H., Yi Dong, Navid Koleini, et al.. (2023). TSC2 S1365A mutation potently regulates CD8+ T cell function and differentiation and improves adoptive cellular cancer therapy. JCI Insight. 8(21). 8 indexed citations
2.
Archer, Katie E., James R. Woods, Luke Harris, et al.. (2019). Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody–Drug Conjugates (ADCs). ACS Medicinal Chemistry Letters. 10(8). 1211–1215. 9 indexed citations
3.
4.
Ab, Olga, Kathleen R. Whiteman, Laura M. Bartle, et al.. (2015). IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. Molecular Cancer Therapeutics. 14(7). 1605–1613. 160 indexed citations
5.
Deckert, Jutta, Marie-Cécile Wetzel, Laura M. Bartle, et al.. (2014). SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies. Clinical Cancer Research. 20(17). 4574–4583. 245 indexed citations
6.
Whiteman, Kathleen R., Holly A. Johnson, Shanqin Xu, et al.. (2009). Abstract #2799: Combination therapy with IMGN901 and lenalidomide plus low-dose dexamethasone is highly effective in multiple myeloma xenograft models. Cancer Research. 69. 2799–2799. 6 indexed citations
7.
Whiteman, Kathleen R., et al.. (2008). Efficacy of IMGN901 (huN901-DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies. Cancer Research. 68. 2146–2146. 11 indexed citations
8.
Park, Peter U., Véronique Blanc, Jutta Deckert, et al.. (2008). SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies. Blood. 112(11). 2756–2756. 3 indexed citations
9.
Poncet, Delphine, Nathanaël Larochette, Anne‐Laure Pauleau, et al.. (2004). An Anti-apoptotic Viral Protein That Recruits Bax to Mitochondria. Journal of Biological Chemistry. 279(21). 22605–22614. 106 indexed citations
10.
Arnoult, Damien, Laura M. Bartle, Anna Skaletskaya, et al.. (2004). Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria. Proceedings of the National Academy of Sciences. 101(21). 7988–7993. 165 indexed citations
11.
Ojima, Iwao, Xu Geng, X. Ben Wu, et al.. (2002). Tumor-Specific Novel Taxoid−Monoclonal Antibody Conjugates. Journal of Medicinal Chemistry. 45(26). 5620–5623. 88 indexed citations
12.
Hayajneh, Wail, Anamaris M. Colberg‐Poley, Anna Skaletskaya, et al.. (2001). The Sequence and Antiapoptotic Functional Domains of the Human Cytomegalovirus UL37 Exon 1 Immediate Early Protein Are Conserved in Multiple Primary Strains. Virology. 279(1). 233–240. 79 indexed citations
13.
Skaletskaya, Anna, Laura M. Bartle, Thomas Chittenden, et al.. (2001). A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proceedings of the National Academy of Sciences. 98(14). 7829–7834. 351 indexed citations
14.
15.
Vater, Carol A., K.B.M. Reid, Laura M. Bartle, & Victor S. Goldmacher. (1995). Characterization of Antibody Binding to Cell Surface Antigens Using a Plasma Membrane-Bound Plate Assay. Analytical Biochemistry. 224(1). 39–50. 6 indexed citations
16.
17.
Vater, Carol A., Laura M. Bartle, John Leszyk, John M. Lambert, & Victor S. Goldmacher. (1995). Ricin A Chain Can Be Chemically Cross-linked to the Mammalian Ribosomal Proteins L9 and L10e. Journal of Biological Chemistry. 270(21). 12933–12940. 48 indexed citations
18.
Ghezzi, Pietro, Roberto Bertini, Manuela Mengozzi, et al.. (1993). Serum amyloid A induction in tumor-bearing mice: Evidence for a tumor- derived mediator. International Journal of Immunopathology and Pharmacology. 6(3). 169–186. 5 indexed citations
19.
20.
Rokita, Hanna, et al.. (1992). Differential effect of interleukin-1 on interleukin-6-stimulated alpha-1-antichymotrypsin expression in human hepatoma cell lines.. PubMed. 30(4). 161–3. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Chittenden Breakdown of academic impact, for papers by William McCulloch Breakdown of academic impact, for papers by Jean-Philippe Stéphan Breakdown of academic impact, for papers by David Maussang Breakdown of academic impact, for papers by Marianne Kraus Breakdown of academic impact, for papers by Rémi Fagard Breakdown of academic impact, for papers by Christopher J. Farady Breakdown of academic impact, for papers by Dorothy Hudig Breakdown of academic impact, for papers by Denis Martinvalet Breakdown of academic impact, for papers by Jens Dhein
Rankless by CCL
2026